BR112017005089A2 - associação de um agente antimicrobiano e de um composto de fórmula i para sua utilização - Google Patents

associação de um agente antimicrobiano e de um composto de fórmula i para sua utilização

Info

Publication number
BR112017005089A2
BR112017005089A2 BR112017005089-7A BR112017005089A BR112017005089A2 BR 112017005089 A2 BR112017005089 A2 BR 112017005089A2 BR 112017005089 A BR112017005089 A BR 112017005089A BR 112017005089 A2 BR112017005089 A2 BR 112017005089A2
Authority
BR
Brazil
Prior art keywords
compound
antimicrobial agent
strain
formula
combination
Prior art date
Application number
BR112017005089-7A
Other languages
English (en)
Other versions
BR112017005089B1 (pt
Inventor
Tesse Nicolas
Original Assignee
Septeos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Septeos filed Critical Septeos
Publication of BR112017005089A2 publication Critical patent/BR112017005089A2/pt
Publication of BR112017005089B1 publication Critical patent/BR112017005089B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção tem como objeto um agente antimicrobiano potencializado para sua utilização no tratamento de uma infecção microbiana, distinguido pelo fato de que se utiliza em associação com o agente antimicrobiano um composto que corresponde à seguinte fórmula i: (i) em uma razão mássica, composto de fórmula (i):agente antimicrobiano, que varia de 8:1 a 1:10 e em que a infecção microbiana é induzida nomeadamente por um patógeno de estirpe a e que, nessa estirpe a, a concentração de composto (i) corresponde à seguinte equação: [c] < [cmi] / x, em que [c] é a concentração de acordo com a invenção de composto (i) a ser utilizada na estirpe a, [cmi] é a cmi medida para o composto (i), sozinho, nessa estirpe a, x é superior ou igual a 100, vantajosamente a 1.000, mais vantajosamente x está compreendido entre 2.000 e 10.000, ou superior a 50.000.
BR112017005089-7A 2014-09-15 2015-09-15 Uso de uma associação de um agente antimicrobiano e de um composto, e associação de um agente antimicrobiano e de cineol BR112017005089B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1458663 2014-09-15
FR1458663A FR3025719A1 (fr) 2014-09-15 2014-09-15 Antimicrobiens potentialises
FR1462136A FR3025720B1 (fr) 2014-09-15 2014-12-09 Antimicrobiens potentialises
FR1462136 2014-12-09
PCT/EP2015/071093 WO2016041958A1 (fr) 2014-09-15 2015-09-15 Antimicrobiens potentialises

Publications (2)

Publication Number Publication Date
BR112017005089A2 true BR112017005089A2 (pt) 2018-01-23
BR112017005089B1 BR112017005089B1 (pt) 2023-01-10

Family

ID=52130381

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005089-7A BR112017005089B1 (pt) 2014-09-15 2015-09-15 Uso de uma associação de um agente antimicrobiano e de um composto, e associação de um agente antimicrobiano e de cineol

Country Status (7)

Country Link
US (1) US10668043B2 (pt)
EP (1) EP3193936B1 (pt)
CN (1) CN107073124B (pt)
BR (1) BR112017005089B1 (pt)
DK (1) DK3193936T3 (pt)
FR (2) FR3025719A1 (pt)
WO (1) WO2016041958A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048612B1 (fr) 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
US11872216B2 (en) 2016-06-02 2024-01-16 Advanced Scientific Developments Pharmaceutical formulation comprising cineole and amoxicillin
FR3052066B1 (fr) * 2016-06-02 2019-09-13 Advanced Scientific Developements Formulation pharmaceutique de cineol et d'amoxicilline
FR3052065B1 (fr) * 2016-06-02 2019-11-22 Advanced Scientific Developements Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787566A (en) * 1969-07-29 1974-01-22 Holliston Labor Inc Disinfecting aerosol compositions
US6319958B1 (en) 1998-06-22 2001-11-20 Wisconsin Alumni Research Foundation Method of sensitizing microbial cells to antimicrobial compound
US7258878B2 (en) * 2004-12-20 2007-08-21 Kimberly-Clark Worldwide, Inc. Anti-microbial composition and methods of use thereof
WO2006120494A1 (fr) 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol
JP6415052B2 (ja) * 2010-12-09 2018-10-31 セプテオス トランス−シンナムアルデヒドを含む医薬組成物、および感染治療におけるその使用
WO2012076718A1 (en) * 2010-12-09 2012-06-14 Societe De Developpement Scientifique - Sds Anti-microbial composition

Also Published As

Publication number Publication date
FR3025719A1 (fr) 2016-03-18
EP3193936A1 (fr) 2017-07-26
US20180021296A1 (en) 2018-01-25
FR3025720A1 (fr) 2016-03-18
DK3193936T3 (da) 2020-09-21
US10668043B2 (en) 2020-06-02
WO2016041958A1 (fr) 2016-03-24
CN107073124A (zh) 2017-08-18
CN107073124B (zh) 2020-10-13
FR3025720B1 (fr) 2018-11-09
EP3193936B1 (fr) 2020-06-17
BR112017005089B1 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
MA41013A (fr) Compositions comprenant des souches bactériennes
BR112017022021A2 (pt) aplicação de agente anticaspa solúvel em tensoativo
BR112017005840A2 (pt) processos para preparar uma solução aquosa de acrilamida, reduzir concentração de ácido acrílico de uma solução aquosa de acrilamida, solução aquosa de acrilamida, homopolímero ou copolímero de acrilamida, e, solução de um homopolímero e/ou copolímero de acrilamida.
BR112016002233A2 (pt) composições de adoçante
BR112017002370A2 (pt) indóis para uso na infecção pelo vírus da gripe
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
MY165124A (en) Semifluorinated alkane compositions
CO2017013065A2 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
BR112017006671A2 (pt) composição essencialmente livre de água e que compreende pelo menos um esporo que forma agente de controle biológico fúngico, um poliéter de trisiloxano modificado e sílica fumigada ou precipitada.
BR112015021352A2 (pt) composições antimicrobianas
MA35920B1 (fr) Composés destinés au traitement de l&#39;amyotrophie spinale
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
WO2015003816A3 (en) Cystobactamides
BR112016029465A2 (pt) chapa de aço elétrica
BR112018014794A2 (pt) pirimidinas substituídas com arila para uso em infecção pelo vírus influenza
BR112017005089A2 (pt) associação de um agente antimicrobiano e de um composto de fórmula i para sua utilização
BR112016013194A2 (pt) Composições de higiene oral compreendendo carbonato de cálcio e sílica
BR112016006428A2 (pt) anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, métodos para tratamento e/ou profilaxia de infecção por pseudomona e para produzir um anticorpo, agente de diagnóstico para infecção por pseudomona, kit de detecção para pseudomonas aeruginosa, polinucleotídeo, vetor, e, célula hospedeira transformada
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
BR112015023387A2 (pt) composições lipídicas de racecodotril
MX352814B (es) Composiciones para el cuidado oral que comprenden carbonato de calcio y talco.
BR112014030025A2 (pt) composições de polissacarídeo e métodos de uso
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
AU2013408771A8 (en) Prebiotic oral care compositions containing an alkyl glycoside

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2015, OBSERVADAS AS CONDICOES LEGAIS